ALKERMES | ALKS - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
J&J USD 17.83B 388M 2026-06
Malin Corporation EUR 1.1M 400K 2024-12
Merck USD 15.77B 2.4B 2026-06
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Otsuka Holdings JPY 561.64B 49.51B 2026-06
Ovoca Bio EUR 173K 990K 2025-12
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06